| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 07/28/2005 | WO2005067908A2 Memantine for the treatment of mild and mild-to-moderate alzheimer’s disease |
| 07/28/2005 | WO2005067632A2 Lipid compositions and use thereof |
| 07/28/2005 | WO2005067627A2 Cosmetic composition and method for retarding hair growth |
| 07/28/2005 | WO2005067363A2 Use of pyrimidine nucleotides for increasing muscle power |
| 07/28/2005 | WO2005055963A3 Decontamination formulation with sorbent additive |
| 07/28/2005 | WO2005051433B1 Method for treating human tumor cells with a newcastle disease virus strain and a chemotherapeutic agent |
| 07/28/2005 | WO2005041944A3 Methods and compositions for promoting axon regeneration and cell replacement therapy |
| 07/28/2005 | WO2005030935A3 Adjuvant activities of mutants of lt-iia and lt-iib enterotoxin lacking binding to ganglioside |
| 07/28/2005 | WO2005030239A3 Antitumor agent comprising a histone deacetylase inhibitor and a topoisomerase ii inhibitor |
| 07/28/2005 | WO2005027936A3 Pharmaceutical compositions and therapeutical treatment with oligo-beta-(1, 3)-glucans |
| 07/28/2005 | WO2005020983A3 Combination therapy for glycaemic control |
| 07/28/2005 | WO2005001033A3 Tolerance induction and maintenance in hematopoietic stem cell allografts |
| 07/28/2005 | WO2004093828A3 Reverse-turn mimetics and method relating thereto |
| 07/28/2005 | WO2004075852A3 Compositions, combinations, and methods for treating cardiovascular conditions and other associated conditions |
| 07/28/2005 | WO2004002296A3 Therapeutic methods for reducing fat deposition and treating associated conditions |
| 07/28/2005 | US20050166274 Compositions and methods for the diagnosis and treatment of tumor |
| 07/28/2005 | US20050165227 Antiproliferative agents; gene overexpression |
| 07/28/2005 | US20050165219 Related to the thymic stromal cotransporter subfamily; can be used as models for the development of and aid in the identification of therapeutic proteins that modulate transporter activity |
| 07/28/2005 | US20050165109 Pharmaceutical composition with combined active agents and methods for using the same |
| 07/28/2005 | US20050165098 Local anesthetic methods and kits |
| 07/28/2005 | US20050165097 Comprising a local anesthetic, an alpha adrenergic receptor agonist and a low dose of an alpha adrenergic receptor antagonist, for reversing local anesthesia |
| 07/28/2005 | US20050165096 injecting one or more anesthetic and medical drugs into the treatment area under a guidance of the ultrasound imaging tool; massage |
| 07/28/2005 | US20050165091 includes a buffering agent to stabilize and maintain the pH below 9 in an aqueous dispersion; slow the degradation; shelf-life |
| 07/28/2005 | US20050165053 Substituted4-aryl-3-(3-aryl-1-oxo-2-propenyl)-2(1h)-quinolinones and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| 07/28/2005 | US20050165041 Combination for the treatment of airway disorders |
| 07/28/2005 | US20050165039 Fluorinated 4-azasteroid derivatives as androgen receptor modulators |
| 07/28/2005 | US20050165030 Pharmaceutical compositions comprising a multifunctional phosphodiesterase inhibitor and an adenosine uptake inhibitor |
| 07/28/2005 | US20050165025 neuromuscular dysfunction of the lower urinary tract; incontinence, overactive bladder, cystitis; serotonin (5-HT) |
| 07/28/2005 | US20050165016 Piperazinyl-, piperidinyl- and morpholinyl-derivatives as novel inhibitors of histone deacetylase |
| 07/28/2005 | US20050165013 used for inflammatory or respiratory system disorders such as asthma or chronic obstructive pulmonary disease |
| 07/28/2005 | US20050164997 a 3-oxo-androstancarbothioic acid compound; respiaratory system disorder |
| 07/28/2005 | US20050164987 Melatonin combination therapy for improving sleep quality |
| 07/28/2005 | US20050164976 Combination of a cdk inhibitor and 5-fu for the tratment of cancer |
| 07/28/2005 | US20050164960 Administering substituted (beta -D-ribofuranosyl)purines or (beta -D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidines alone or incombination with cidofovir, ribavirin, levovirin, or viramidine, particularly against vaccinia virus or variola virus infections |
| 07/28/2005 | US20050164908 Neuroprotective complex for treatment of cerebral ischemia and injury |
| 07/28/2005 | US20050164395 Synthetic urine and method of manufacturing same |
| 07/28/2005 | US20050164313 Methods and compositions for the detection of cervical cancer |
| 07/28/2005 | US20050164305 Diagnostics and therapeutics for diseases associated with n-formyl peptide receptor like 1 (fprl1) |
| 07/28/2005 | US20050164298 Diagnostics and therapeutics for diseases associated with growth hormone secretagogue receptor(ghs) |
| 07/28/2005 | US20050164291 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 07/28/2005 | US20050164267 Using caudal-1 gene (CDX-1) as diagnostic indicator of stomach or esophageal cancer; immunodiagnostics |
| 07/28/2005 | US20050164263 identification of amino acid sequences and proteins related to MAP/ERK subfamily; gene chip; transgenic nonhuman animal; nucleic acid vector; expression in larynx epithelium, Wilms' tumors of the kidney, pancreas adenocarcinomas, fetal brain, and hippocampus; models for human therapeutic targets |
| 07/28/2005 | US20050164233 Compositions, kits and methods for identification and modulation of type I diabetes |
| 07/28/2005 | US20050164185 Interferon receptor variant for treatment and prevention of cell proliferative, autoimmune and viral diseases; prolonged activation of interferon beta |
| 07/28/2005 | US20050163868 mixtures of plant extracts, cellulose esters, sodium bicarbonate and silica, having improved disintegration and dissolution properties |
| 07/28/2005 | US20050163867 Composition and method of treating gastric ulcers in mammals |
| 07/28/2005 | US20050163865 Food supplement embodiments provide the human body nutritional supplements to intake certain neurotransmitter precursor substrates, thereby enabling patients of all ages to self-regulate their ability to quell perturbations to equilibrium and simultaneously to adverse effects |
| 07/28/2005 | US20050163842 Rosiglitazone and metformin formulations |
| 07/28/2005 | US20050163817 Biomatrix structural containment and fixation systems and methods of use thereof |
| 07/28/2005 | US20050163816 Gas-plasma treatment of a substrate of medical implant; living cells coupled to a treated substrate may produce more of a growth factor than living cells coupled to an untreated substrate |
| 07/28/2005 | US20050163811 highly effective, non-oily solution for facilitating hair growth that comprises a high concentration of Minoxidil, that is not cosmetically unattractive when applied to a treatment area and that does not cause skin irritation in the treatment area |
| 07/28/2005 | US20050163793 Methods for recovering peptides from stress protein-peptide complexes |
| 07/28/2005 | US20050163785 affect cell growth by blocking progression of the cell cycle in G2/M and their use in therapy of cancers which express the antigen |
| 07/28/2005 | US20050163778 Extracorporeal photopheresis in combination with anti-TNF treatment |
| 07/28/2005 | US20050163764 oral administration and mucosal administration and wherein the gastrointestinal injury is treated; bacterial infection and cancer treatments that can cause tissue damage |
| 07/28/2005 | US20050163759 Compositions and methods for ex vivo preservation of blood vessels for vascular grafts using inhibitors of type I and/or type II phosphodiesterases |
| 07/28/2005 | US20050163751 Synergistic mixture with compounds such as interferon, paclitaxel or P-16; side effect reduction |
| 07/28/2005 | US20050163749 Method of pre-sensitizing cancer prior to treatment with radiation and/or chemotherapy and a novel cytokine mixture |
| 07/28/2005 | US20050163746 Heat shock proteins (HSP) activate lymphocytes to produce immunomodulatory cytokines and influence cytokines, chemokines, and surface antigens; drug screening |
| 07/28/2005 | US20050163744 Novel method for down-regulation of amyloid |
| 07/28/2005 | US20050163727 Topical, oral administration; mouthrinses; microbiocides; bactericides; prevents spread of pathogenic oral bacteria, toxins and endotoxins, and resultant inflammatory cytokines and mediators; cardiovascular disease, stroke, atherosclerosis |
| 07/28/2005 | US20050163707 Radio labelled monoclonal antibody human milk fat globule1, binds selectively to polymorphic epithelial mucin; Taxotere chemotherapeutic agent; administered in combination |
| 07/28/2005 | DE10361945A1 Pharmaceutical preparation for the treatment of e.g. severe acute respiratory syndrome |
| 07/28/2005 | DE10360847A1 Medical lubricant gel, useful in ear, nose and throat medicine, urology and gynecology, comprising gel former, care component and antimicrobial |
| 07/28/2005 | DE102004001093A1 Zusammensetzung und Methode einer synergistischen topischen Therapie neuromuskulärer Schmerzen Composition and method of a synergistic topical treatment of neuromuscular pain |
| 07/28/2005 | CA2559352A1 Lipid compositions and use thereof |
| 07/28/2005 | CA2553988A1 Pharmaceutical compositions comprising higher primary aliphatic alcohols and hmg coa reductase inhibitor and process of preparation thereof |
| 07/28/2005 | CA2553629A1 Combinations of serotonin reuptake inhibitors and imidazoline-i2-agonists |
| 07/28/2005 | CA2553609A1 Methods and compositions for modulating a steroid receptor |
| 07/28/2005 | CA2552889A1 Iron supplement and utilization of the same |
| 07/28/2005 | CA2552539A1 Use of substituted pyrimido[5,4-d]pyrimidines for the treatment of respiratory diseases |
| 07/28/2005 | CA2552471A1 Combination of crf antagonists and 5-ht 1b receptor antagonists |
| 07/28/2005 | CA2551689A1 Memantine for the treatment of mild and mild-to-moderate alzheimer's disease |
| 07/28/2005 | CA2550625A1 Nutrient compositions and methods for enhanced effectiveness of the immune system |
| 07/28/2005 | CA2547080A1 Heterocyclic protein kinase inhibitors and uses thereof |
| 07/27/2005 | EP1557410A2 Bacterial gyrase inhibitors and uses thereof |
| 07/27/2005 | EP1557178A1 Use of sglt homolog |
| 07/27/2005 | EP1557174A1 Composition containing eosinophil cationic protein |
| 07/27/2005 | EP1557173A1 Soluble CTLA4 mutant molecules and uses thereof |
| 07/27/2005 | EP1557165A1 Combination drug |
| 07/27/2005 | EP1557163A1 Therapeutic causing contraction of mucosal tissue, method of treating diseases relating to mucosal tissues, injector and therapeutic set |
| 07/27/2005 | EP1556399A2 Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
| 07/27/2005 | EP1556357A1 Compounds, compositions, and methods |
| 07/27/2005 | EP1556088A2 Compositions for cancer treatment |
| 07/27/2005 | EP1556080A1 Use of convertase inhibitors in the treatment of fibrosis and scarring |
| 07/27/2005 | EP1556073A2 Method and composition for preventing and treating solid tumors |
| 07/27/2005 | EP1556061A2 Photokinetic delivery of biologically active substances using pulsed incoherent light |
| 07/27/2005 | EP1556051A2 Synergistic methods and compositions for treating cancer |
| 07/27/2005 | EP1556044A2 Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain |
| 07/27/2005 | EP1556042A2 Combinations of benzodithiazoles and cox-2 inhibitors for the treatment of pain |
| 07/27/2005 | EP1556033A1 Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases |
| 07/27/2005 | EP1556023A1 Nutritional or therapeutic compositions |
| 07/27/2005 | EP1556022A1 Aqueous 2,6-diisopropylphenol pharmaceutical compositions |
| 07/27/2005 | EP1556011A1 Therapeutic compositions |
| 07/27/2005 | EP1556004A2 Pharmaceutical compositions for buccal delivery of pain relief medications |
| 07/27/2005 | EP1556003A2 Methods of administering and enhancing absorption of pharmaceutical agents |
| 07/27/2005 | EP1556001A2 Therapeutic compositions for drug delivery to and through covering epithelia |
| 07/27/2005 | EP1379523B1 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin ii receptor antagonists |
| 07/27/2005 | EP1339711B1 Aminothiazoles and their use as adenosine receptor antagonists |
| 07/27/2005 | EP1320295A4 Collagen/polysaccharide bilayer matrix |